Your browser doesn't support javascript.
loading
The innate sensor ZBP1-IRF3 axis regulates cell proliferation in multiple myeloma.
Ponnusamy, Kanagaraju; Tzioni, Maria Myrsini; Begum, Murshida; Robinson, Mark E; Caputo, Valentina S; Katsarou, Alexia; Trasanidis, Nikolaos; Xiao, Xiaolin; Kostopoulos, Ioannis V; Iskander, Deena; Roberts, Irene; Trivedi, Pritesh; Auner, Holger W; Naresh, Kikkeri; Chaidos, Aristeidis; Karadimitris, Anastasios.
Afiliação
  • Ponnusamy K; Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London.
  • Tzioni MM; Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London.
  • Begum M; Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London.
  • Robinson ME; Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London.
  • Caputo VS; Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London.
  • Katsarou A; Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Foundation Trust, London.
  • Trasanidis N; Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London.
  • Xiao X; Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London.
  • Kostopoulos IV; Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom; Section of Animal and Human Physiology, National and Kapodestrian University of Athens, Department of Biology, School of Scienc
  • Iskander D; Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Foundation Trust, London.
  • Roberts I; Department of Paediatrics and MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford and BRC Blood Theme, NIHR Oxford Biomedical Centre, Oxford.
  • Trivedi P; Department of Cellular and Molecular Pathology, Northwest London Pathology, Imperial College Healthcare NHS Trust, London.
  • Auner HW; Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Foundation Trust, London.
  • Naresh K; Department of Cellular and Molecular Pathology, Northwest London Pathology, Imperial College Healthcare NHS Trust, London.
  • Chaidos A; Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Foundation Trust, London.
  • Karadimitris A; Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Foundation Trust, London. a.karadimitris@imper
Haematologica ; 107(3): 721-732, 2022 03 01.
Article em En | MEDLINE | ID: mdl-33596642
ABSTRACT
Multiple myeloma is a malignancy of plasma cells initiated and driven by primary and secondary genetic events. However, myeloma plasma cell survival and proliferation might be sustained by non-genetic drivers. Z-DNA-binding protein 1 (ZBP1; also known as DAI) is an interferon-inducible, Z-nucleic acid sensor that triggers RIPK3-MLKL-mediated necroptosis in mice. ZBP1 also interacts with TBK1 and the transcription factor IRF3 but the function of this interaction is unclear, and the role of the ZBP1-IRF3 axis in cancer is not known. Here we show that ZBP1 is selectively expressed in late B-cell development in both human and murine cells and it is required for optimal T-cell-dependent humoral immune responses. In myeloma plasma cells, the interaction of constitutively expressed ZBP1 with TBK1 and IRF3 results in IRF3 phosphorylation. IRF3 directly binds and activates cell cycle genes, in part through co-operation with the plasma cell lineage-defining transcription factor IRF4, thereby promoting myeloma cell proliferation. This generates a novel, potentially therapeutically targetable and relatively selective myeloma cell addiction to the ZBP1-IRF3 axis. Our data also show a noncanonical function of constitutive ZBP1 in human cells and expand our knowledge of the role of cellular immune sensors in cancer biology.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo Limite: Animals / Humans Idioma: En Revista: Haematologica Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo Limite: Animals / Humans Idioma: En Revista: Haematologica Ano de publicação: 2022 Tipo de documento: Article